MedTrace Logo

Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer

NCT00268255 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2013-04-16

No results posted yet for this study

Summary

RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Gefitinib may make tumor cells more sensitive to radiation therapy. Giving gefitinib together with radiation therapy may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of radiation therapy when given together with gefitinib and to see how well they work in treating patients with inoperable stage I or stage II non-small cell lung cancer.

Conditions

Interventions

DRUG

gefitinib

PROCEDURE

adjuvant therapy

PROCEDURE

enzyme inhibitor therapy

PROCEDURE

neoadjuvant therapy

PROCEDURE

protein tyrosine kinase inhibitor therapy

PROCEDURE

radiation therapy

PROCEDURE

radiosensitization

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Barbara Ann Karmanos Cancer Institute

    lead OTHER

Principal Investigators

  • Andrew T. Turrisi, MD · Barbara Ann Karmanos Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00268255 on ClinicalTrials.gov